



Diversity in Cancer Research Seminar

April 27, 2022

2:00 – 4:00 pm

“New Cell Cycle Inhibitors Target Aneuploidy in Cancer Therapy”

Attend In-Person (masks required)

Howard University Interdisciplinary Research Building Multipurpose Room

2201 Georgia Avenue, NW Washington, DC 20059

Parking available 8th Street NW between Barry Pl. & V street

[Attend Virtually Via Zoom](#)



RESEARCH FUNDING OPPORTUNITIES

- **PILOT GRANTS**
Small grants to test feasibility and collect preliminary data
- **CLINICIAN SCIENTIST AWARDS**
Protected time for mentored research
- **POST-DOCTORAL FELLOWSHIPS**
Mentored research training
- **MASTER SCHOLAR AWARDS**
MPH student practicum or fellowship

All disciplines are encouraged to apply

LEARN MORE HERE

[**Diversity In Cancer Research**](#)

Howard University Cancer Center
CancerCenter@howard.edu
(202) 806-2878

GUEST SPEAKER

Dr. Dmitrovsky is an American Cancer Society (ACS) Professor and former provost and executive vice president of the University of Texas MD Anderson Cancer Center.

He developed the genetic test used to diagnose and monitor therapy for acute promyelocytic leukemia and had a key role in establishing curative retinoic acid-based differentiation therapy as an FDA approved treatment.

Dr. Dmitrovsky implemented robust programs to support the training and scholarship of research nurses, undergraduate and graduate students, fellows and faculty.



Ethan Dmitrovsky, MD

American Cancer Society Professor
President, Leidos Biomedical Research
Director, Frederick National Laboratory for Cancer Research

The ACS Diversity in Cancer Research Grant supports career development and mentoring in cancer disparities research at Howard University

